Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Letter from the Editor-in-Chief: Growth of the Journal.

Mouradian MM.

Neurotherapeutics. 2019 Sep 13. doi: 10.1007/s13311-019-00783-8. [Epub ahead of print] No abstract available.

PMID:
31520305
2.

Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.

Beck G, Singh A, Zhang J, Potts LF, Woo JM, Park ES, Mochizuki H, Mouradian MM, Papa SM.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18664-18672. doi: 10.1073/pnas.1907810116. Epub 2019 Aug 27.

PMID:
31455727
3.

Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Nakamori M, Junn E, Mochizuki H, Mouradian MM.

Neurotherapeutics. 2019 Apr;16(2):287-298. doi: 10.1007/s13311-019-00714-7. Review.

PMID:
30756362
4.

Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.

Yan R, Zhang J, Park HJ, Park ES, Oh S, Zheng H, Junn E, Voronkov M, Stock JB, Mouradian MM.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12053-E12062. doi: 10.1073/pnas.1813365115. Epub 2018 Dec 3.

5.

The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress.

Oh SE, Park HJ, He L, Skibiel C, Junn E, Mouradian MM.

Redox Biol. 2018 Oct;19:62-73. doi: 10.1016/j.redox.2018.07.021. Epub 2018 Aug 3.

6.

Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Park HJ, Lee KW, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110.

7.

Regulation of Signal Transduction by DJ-1.

Oh SE, Mouradian MM.

Adv Exp Med Biol. 2017;1037:97-131. doi: 10.1007/978-981-10-6583-5_8.

8.

Letter From the Editor-in-Chief: Journal Transition in the Digital Age.

Mouradian MM.

Neurotherapeutics. 2017 Oct;14(4):831. doi: 10.1007/s13311-017-0578-z. No abstract available.

9.

Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction.

Oh SE, Mouradian MM.

Redox Biol. 2018 Apr;14:211-217. doi: 10.1016/j.redox.2017.09.008. Epub 2017 Sep 18. Review.

10.

Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.

Park HJ, Lee KW, Park ES, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

Ann Clin Transl Neurol. 2016 Sep 7;3(10):769-780. eCollection 2016 Oct.

11.

Silica-coated magnetic nanoparticles impair proteasome activity and increase the formation of cytoplasmic inclusion bodies in vitro.

Phukan G, Shin TH, Shim JS, Paik MJ, Lee JK, Choi S, Kim YM, Kang SH, Kim HS, Kang Y, Lee SH, Mouradian MM, Lee G.

Sci Rep. 2016 Jul 5;6:29095. doi: 10.1038/srep29095.

12.

Rare genetic variants support mitochondrial dysfunction in Lewy body disorders.

Wider C, Mouradian MM.

Neurology. 2015 Dec 8;85(23):2002-3. doi: 10.1212/WNL.0000000000002182. Epub 2015 Nov 11. No abstract available.

PMID:
26561295
13.

Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.

Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, Voronkov M, Papa SM, Mouradian MM.

Ann Neurol. 2015 Jun;77(6):930-41. doi: 10.1002/ana.24375. Epub 2015 Mar 27.

14.

MicroRNA-7 Promotes Glycolysis to Protect against 1-Methyl-4-phenylpyridinium-induced Cell Death.

Chaudhuri AD, Kabaria S, Choi DC, Mouradian MM, Junn E.

J Biol Chem. 2015 May 8;290(19):12425-34. doi: 10.1074/jbc.M114.625962. Epub 2015 Mar 26.

15.

Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease.

Kabaria S, Choi DC, Chaudhuri AD, Mouradian MM, Junn E.

FEBS Lett. 2015 Jan 30;589(3):319-25. doi: 10.1016/j.febslet.2014.12.014. Epub 2014 Dec 23.

16.

MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.

Aung LL, Mouradian MM, Dhib-Jalbut S, Balashov KE.

J Neuroimmunol. 2015 Jan 15;278:185-9. doi: 10.1016/j.jneuroim.2014.11.004. Epub 2014 Nov 10.

17.

MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA.

Choi DC, Chae YJ, Kabaria S, Chaudhuri AD, Jain MR, Li H, Mouradian MM, Junn E.

J Neurosci. 2014 Sep 17;34(38):12725-37. doi: 10.1523/JNEUROSCI.0985-14.2014.

18.

Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice.

Lee KW, Woo JM, Im JY, Park ES, He L, Ichijo H, Junn E, Mouradian MM.

Neurobiol Aging. 2015 Jan;36(1):519-26. doi: 10.1016/j.neurobiolaging.2014.07.034. Epub 2014 Jul 31.

19.

A new quantitative rating scale for dyskinesia in nonhuman primates.

Potts LF, Uthayathas S, Greven AC, Dyavarshetty B, Mouradian MM, Papa SM.

Behav Pharmacol. 2015 Feb;26(1-2):109-16. doi: 10.1097/FBP.0000000000000084.

20.

Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.

Grosso H, Woo JM, Lee KW, Im JY, Masliah E, Junn E, Mouradian MM.

FASEB J. 2014 Oct;28(10):4280-91. doi: 10.1096/fj.14-251413. Epub 2014 Jun 26.

21.

Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?

Lewitt PA, Mouradian MM.

Neurology. 2014 May 6;82(18):1574-5. doi: 10.1212/WNL.0000000000000390. Epub 2014 Apr 9.

PMID:
24719487
22.

The role of oxidative stress in Parkinson's disease.

Dias V, Junn E, Mouradian MM.

J Parkinsons Dis. 2013;3(4):461-91. doi: 10.3233/JPD-130230. Review.

23.

Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease.

Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut MM, Fernandez JR, Voronkov M, Junn E, Braithwaite SP, Stock JB, Mouradian MM.

Neurotherapeutics. 2013 Jan;10(1):143-53. doi: 10.1007/s13311-012-0165-2.

24.

α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.

Braithwaite SP, Stock JB, Mouradian MM.

Rev Neurosci. 2012 Mar 21;23(2):191-8. doi: 10.1515/revneuro-2011-0067. Review.

PMID:
22499677
25.

DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.

Im JY, Lee KW, Woo JM, Junn E, Mouradian MM.

Hum Mol Genet. 2012 Jul 1;21(13):3013-24. doi: 10.1093/hmg/dds131. Epub 2012 Apr 5.

26.

Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.

Braithwaite SP, Voronkov M, Stock JB, Mouradian MM.

Neurochem Int. 2012 Nov;61(6):899-906. doi: 10.1016/j.neuint.2012.01.031. Epub 2012 Feb 8. Review.

PMID:
22342821
27.

Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation.

Lee KW, Zhao X, Im JY, Grosso H, Jang WH, Chan TW, Sonsalla PK, German DC, Ichijo H, Junn E, Mouradian MM.

PLoS One. 2012;7(1):e29935. doi: 10.1371/journal.pone.0029935. Epub 2012 Jan 10.

28.

MicroRNAs in Parkinson's disease.

Mouradian MM.

Neurobiol Dis. 2012 May;46(2):279-84. doi: 10.1016/j.nbd.2011.12.046. Epub 2012 Jan 5. Review.

PMID:
22245218
29.

Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.

Grosso H, Mouradian MM.

Pharmacol Ther. 2012 Mar;133(3):392-410. doi: 10.1016/j.pharmthera.2011.12.003. Epub 2011 Dec 22. Review.

PMID:
22212614
30.

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease.

Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D.

Mov Disord. 2012 Feb;27(2):284-8. doi: 10.1002/mds.23983. Epub 2011 Dec 9.

PMID:
22161845
31.

MicroRNAs in neurodegenerative diseases and their therapeutic potential.

Junn E, Mouradian MM.

Pharmacol Ther. 2012 Feb;133(2):142-50. doi: 10.1016/j.pharmthera.2011.10.002. Epub 2011 Oct 8. Review.

32.

Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.

Kim YM, Jang WH, Quezado MM, Oh Y, Chung KC, Junn E, Mouradian MM.

J Neurol Sci. 2011 Aug 15;307(1-2):157-61. doi: 10.1016/j.jns.2011.04.015. Epub 2011 Jun 8.

33.

Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model.

Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

J Neurosci. 2011 May 11;31(19):6963-71. doi: 10.1523/JNEUROSCI.6513-10.2011.

34.

Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation.

Oh Y, Kim YM, Mouradian MM, Chung KC.

Brain Res. 2011 Mar 24;1381:78-89. doi: 10.1016/j.brainres.2011.01.039. Epub 2011 Jan 20.

PMID:
21256122
35.

Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, Papa SM.

J Neurosci. 2010 May 26;30(21):7335-43. doi: 10.1523/JNEUROSCI.0252-10.2010.

36.

MicroRNAs in neurodegenerative disorders.

Junn E, Mouradian MM.

Cell Cycle. 2010 May;9(9):1717-21. Epub 2010 May 25.

PMID:
20404550
37.

DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex.

Im JY, Lee KW, Junn E, Mouradian MM.

Neurosci Res. 2010 Jul;67(3):203-8. doi: 10.1016/j.neures.2010.04.002. Epub 2010 Apr 10.

38.

Repression of alpha-synuclein expression and toxicity by microRNA-7.

Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13052-7. doi: 10.1073/pnas.0906277106. Epub 2009 Jul 23.

39.

Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone.

Lee SH, Jang MK, Kim OS, Lee OH, Kim NY, Yoo KH, Lee DG, Shong YH, Mouradian MM.

J Steroid Biochem Mol Biol. 2009 May;115(1-2):30-5. doi: 10.1016/j.jsbmb.2009.02.013. Epub 2009 Mar 4.

PMID:
19429458
40.

Mitochondrial localization of DJ-1 leads to enhanced neuroprotection.

Junn E, Jang WH, Zhao X, Jeong BS, Mouradian MM.

J Neurosci Res. 2009 Jan;87(1):123-9. doi: 10.1002/jnr.21831.

41.

Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene.

Lee SH, Jang MK, Lee OH, Kim OS, Kim YM, Yajima S, Lee YC, Mouradian MM.

Mol Cell Endocrinol. 2008 Jul 16;289(1-2):23-8. doi: 10.1016/j.mce.2008.03.011. Epub 2008 Apr 4.

PMID:
18472212
42.

Advances in gene therapy for movement disorders.

Mochizuki H, Yasuda T, Mouradian MM.

Neurotherapeutics. 2008 Apr;5(2):260-9. doi: 10.1016/j.nurt.2008.01.005. Review.

43.

Localization of CKII beta subunits in Lewy bodies of Parkinson's disease.

Ryu MY, Kim DW, Arima K, Mouradian MM, Kim SU, Lee G.

J Neurol Sci. 2008 Mar 15;266(1-2):9-12. Epub 2007 Sep 19.

PMID:
17884098
44.

Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases.

Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T, Yong VW.

J Neuroimmunol. 2006 Jul;176(1-2):198-215.

PMID:
16983747
45.

Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death.

Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H, Mouradian MM.

Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9691-6. Epub 2005 Jun 27.

46.

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN.

Mov Disord. 2005 Aug;20(8):932-6.

PMID:
15791634
47.

Should levodopa be infused into the duodenum?

Mouradian MM.

Neurology. 2005 Jan 25;64(2):182-3. No abstract available.

PMID:
15668409
48.

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN.

Mov Disord. 2004 Oct;19(10):1183-6.

PMID:
15390018
49.

Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system.

Dhib-Jalbut S, Mouradian MM.

Expert Opin Biol Ther. 2004 May;4(5):669-75. Review.

PMID:
15155158
50.

Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice.

Makar TK, Trisler D, Eglitis MA, Mouradian MM, Dhib-Jalbut S.

Neurosci Lett. 2004 Feb 19;356(3):215-9.

PMID:
15036633

Supplemental Content

Loading ...
Support Center